EUVIMEDEUVIMED entdecken
Crossref

ROS ‐Responsive Quercetin Nanoparticles Improve the Prognosis of Traumatic Brain Injury by Inhibiting Aberrant Nrf2‐Keap1 Signaling Pathway Activation

YiFan Lei, Rongrong Dou, Cuihuan Ma, Yan Fang, Zhichao Wang, Yu Gao, Chang Cai, Xiefeng Wang, Yongkang Zhang, Xianhua Fu

Journal of Biomedical Materials Research Part A · 2026-07 · 114 (7)

DOI: 10.1002/jbm.a.70123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biomedical Materials Research Part A, online erschienen am 04.07.2026. Verfasst von YiFan Lei und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, Jiangsu, People's Republic of China. Hauptthemen laut MEDLINE: Quercetin, NF-E2-Related Factor 2, Brain Injuries, Traumatic, Kelch-Like ECH-Associated Protein 1. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Suqian Sci&Tech Program, Medical Scientific Research Projects of the Jiangsu Provincial Health Commission, Jiangsu High-level Hospital Pairing Assistance Research Initiative.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Traumatic brain injury (TBI) is one of the leading causes of mortality and disability worldwide, with secondary injury recognized as a critical therapeutic target. Quercetin (QR), a natural flavonoid, exerts antioxidant and anti‐inflammatory effects by modulating the Nrf2–Keap1 pathway and shows neuroprotective potential in various neurological disorders. In this study, network pharmacology analysis identified 496 overlapping targets of QR and TBI, further highlighting the pivotal role of the Nrf2–Keap1 pathway in TBI treatment. However, the poor blood–brain barrier (BBB) permeability and low bioavailability of QR hinder effective brain‐targeted delivery and limit its clinical translation. To address these challenges, we developed CAQK peptide‐modified, reactive oxygen species (ROS)‐responsive nanoparticles (C‐PPS/Q), using PPS 120 as the core for targeted QR delivery. C‐PPS/Q exhibited ROS‐triggered QR release, significantly enhanced HT22 cell uptake in vitro, reduced ROS levels and apoptosis. In a TBI mouse model, C‐PPS/Q specifically accumulated at the lesion site, prolonged the half‐life of QR, demonstrated excellent biocompatibility, preserved BBB integrity, attenuated neuroinflammation, inhibited aberrant Nrf2‐Keap1 pathway activation, and markedly improved neurological function. Collectively, C‐PPS/Q nanoparticles effectively mitigate secondary brain injury after TBI and represent a promising brain‐targeted therapeutic strategy for TBI management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

QuercetinNF-E2-Related Factor 2Brain Injuries, TraumaticKelch-Like ECH-Associated Protein 1Reactive Oxygen SpeciesSignal TransductionNanoparticlesAnimalsMiceMalePrognosisCell LineHumansMice, Inbred C57BL

Stichwörter der Autor:innen

Nrf2‐Keap1 signaling pathwaynanoparticlesquercetintraumatic brain injury

Substanzen

QuercetinNF-E2-Related Factor 2Kelch-Like ECH-Associated Protein 1Reactive Oxygen SpeciesKeap1 protein, mouseNfe2l2 protein, mouse

Autor:innen und Institutionen

  • Department of Pathology, Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, Jiangsu, People's Republic of China.
  • Dalian Medical University, Dalian, Liaoning, People's Republic of China.
  • Department of Neurosurgery, Suqian Hospital Affiliated to Xuzhou Medical University, Suqian, Jiangsu, People's Republic of China.
  • Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, People's Republic of China.
  • Department of Neurosurgery, Jiangsu Province (Suqian) Hospital, Suqian, Jiangsu, People's Republic of China.
  • Department of Neurosurgery, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, People's Republic of China.

Förderung

  • Suqian Sci&Tech Program
  • Medical Scientific Research Projects of the Jiangsu Provincial Health Commission
  • Jiangsu High-level Hospital Pairing Assistance Research Initiative
  • General Research Project (Youth Fund) of Jiangsu Provincial Health Commission

Zitieren

APA

Lei, Y., Dou, R., Ma, C., Fang, Y., Wang, Z., Gao, Y., Cai, C., Wang, X., Zhang, Y., & Fu, X. (2026). ROS ‐Responsive Quercetin Nanoparticles Improve the Prognosis of Traumatic Brain Injury by Inhibiting Aberrant Nrf2‐Keap1 Signaling Pathway Activation. Journal of Biomedical Materials Research Part A, 114(7). https://doi.org/10.1002/jbm.a.70123

Vancouver

Lei Y, Dou R, Ma C, Fang Y, Wang Z, Gao Y, et al. ROS ‐Responsive Quercetin Nanoparticles Improve the Prognosis of Traumatic Brain Injury by Inhibiting Aberrant Nrf2‐Keap1 Signaling Pathway Activation. Journal of Biomedical Materials Research Part A. 2026;114(7). doi:10.1002/jbm.a.70123

BibTeX
@article{Lei2026,
  author = {Lei, YiFan and Dou, Rongrong and Ma, Cuihuan and Fang, Yan and Wang, Zhichao and Gao, Yu and Cai, Chang and Wang, Xiefeng and Zhang, Yongkang and Fu, Xianhua},
  title = {ROS ‐Responsive Quercetin Nanoparticles Improve the Prognosis of Traumatic Brain Injury by Inhibiting Aberrant Nrf2‐Keap1 Signaling Pathway Activation},
  journal = {Journal of Biomedical Materials Research Part A},
  year = {2026},
  volume = {114},
  number = {7},
  doi = {10.1002/jbm.a.70123}
}
Kostenlos starten →